Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;8(6):274-93.
doi: 10.1177/1756285615605429.

Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes

Jan Lycke  1
Affiliations
Review

Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes

Jan Lycke. Ther Adv Neurol Disord. 2015 Nov.

Abstract

Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune cells or other molecules involved in pathogenic pathways with extraordinary specificity. Natalizumab and alemtuzumab are the only two currently approved mAbs for the treatment of MS, having demonstrated significant reduction in clinical and magnetic resonance imaging disease activity and disability in clinical studies. Ocrelizumab and daclizumab are in the late stages of phase III trials, and several other mAbs are in the early stages of clinical evaluation. mAbs have distinct structural characteristics (e.g. chimeric, humanized, fully human) and unique targets (e.g. blocking interactions, induction of signal transduction by receptor binding, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity) conferring different mechanisms of action in MS. Because of these differences, mAbs for MS do not constitute a single treatment class; each must be considered individually when selecting appropriate therapy. Furthermore, in reviewing the data from clinical studies of mAbs, attention should be drawn to use of different comparators (e.g. placebo or interferon β-1a) and study designs. Each mAb treatment has a unique administration schedule. In the decision to select the appropriate treatment for each individual MS patient, careful review of the benefits relative to risks of mAbs is balanced against the risk of development of MS-associated disability.

Keywords: antibodies; autoimmunity; monoclonal; multiple sclerosis; therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:J.L. reports having received travel support and/or lecture honoraria from Bayer Schering Pharma, Biogen Idec, Novartis and Genzyme/Sanofi Aventis, served on scientific advisory boards for Almirall, Teva, Biogen Idec and Genzyme/Sanofi Aventis, and received unconditional research grants from Biogen Idec and Novartis. Editorial support for this manuscript was provided by Aji Nair, PhD, Genzyme Corporation, and Amy Zannikos, PharmD, CMPP, and Kristen W. Quinn, PhD, of Peloton Advantage, LLC, and was funded by Genzyme, a Sanofi company. The author was responsible for all content and editorial decisions and received no honoraria related to the development of this publication.

References

    1. Abbas M., Lalive P., Chofflon M., Simon H., Chizzolini C., Ribi C. (2011) Hypereosinophilia in patients with multiple sclerosis treated with natalizumab. Neurology 77: 1561–1564. - PubMed
    1. Antoniol C., Jilek S., Schluep M., Mercier N., Canales M., Le G., et al. (2012) Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 79: 2258–2264. - PubMed
    1. Arkema E., van Vollenhoven R., Askling J. (2012) Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis 71: 1865–1867. - PubMed
    1. Arnold D., Fisher E., Cohen J., Barkhof F., Selmaj K., Margolin D., et al. (2014) Alemtuzumab improves brain MRI outcomes in patients with active relapsing-remitting multiple sclerosis: three-year follow-up of the CARE-MS studies [poster P008]. Presented at the 66th Annual Meeting of the American Academy of Neurology, 26 April to 3 May 2014, Philadelphia, PA.
    1. Arnold D., Traboulsee A., Coles A., Cohen J., Fox E., Hartung H., et al. (2015) Durable effect of alemtuzumab on MRI activity in treatment-naive active relapsing-remitting multiple sclerosis patients: 4-year follow-up of CARE-MS I [poster P7.246]. Presented at the Annual Meeting of the American Academy of Neurology, 18–25 April 2015, Washington DC.

LinkOut - more resources